LENZ Therapeutics has announced that Everest Medicines will acquire the rights to develop and commercialize its presbyopia treatment, VIZZ (LNZ100), in Greater China. The New Drug Application was submitted in September 2025, with approval expected in Q1 2027. LENZ is set to receive up to $85 million in regulatory and sales milestones along with royalties. Everest emphasizes the product’s potential to address unmet medical needs in ophthalmology, aiming to make this innovative treatment accessible to millions suffering from presbyopia.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://ir.lenz-tx.com/news-events/press-releases/detail/57/lenz-therapeutics-announces-everest-medicines-acquired-rights-to-develop-and-commercialize-vizz-lnz100-in-greater-china
